AtCor Medical has announced it has received FDA clearance a new blood pressure cuff-based system, according to a news release.
The SphygmoCor XCEL device measures brachial and central aortic blood pressures. The system also perform pulse wave velocity measurement, a test used to measure aortic stiffness.
SphygmoCor® XCEL was introduced in the United States in demonstrations at the American Society of Nephrology conference in San Diego earlier this month.
"The reaction from physicians and from our pharmaceutical clinical trials customers has been extremely positive," said Duncan Ross, AtCor Medical CEO, in the release. "SphygmoCor XCEL offers users the gold standard in pulse wave analysis and pulse wave velocity measurement, featured in over 600 published studies, in a cuff-based system that is very easy to use. SphygmoCor XCEL sequentially measures brachial blood pressure and central aortic pressure, providing comprehensive cardiovascular data for diagnosis, risk assessment and drug therapy management."
AtCor Medical is headquartered in Australia.
Related Articles on FDA Clearances:
InSightec Receives FDA Clearance for Bone Pain Ultrasound Therapy
Raiing Receives FDA Clearance for Wireless Thermometer
Cook Medical Receives FDA Approval for Drug-Eluting Stent